scholarly journals Monoblock and twinblock mandibular advancement devices in the treatment of obstructive sleep apnea

2018 ◽  
Vol 9 (3) ◽  
Author(s):  
Ignazio La Mantia
2021 ◽  
Vol 56 ◽  
pp. 101407
Author(s):  
Micheline M.D. De Meyer ◽  
Olivier M. Vanderveken ◽  
Sonia De Weerdt ◽  
Luc A.M. Marks ◽  
Bernadita A. Cárcamo ◽  
...  

Health ◽  
2013 ◽  
Vol 05 (08) ◽  
pp. 1-5 ◽  
Author(s):  
Tiina-Riitta Vuorjoki-Ranta ◽  
Frank Lobbezoo ◽  
Henri Tuomilehto ◽  
Mauno Könönen ◽  
Antti Pihakari ◽  
...  

2019 ◽  
Vol 24 (3) ◽  
pp. 99-109 ◽  
Author(s):  
Jorge Faber ◽  
Carolina Faber ◽  
Ana Paula Faber

ABSTRACT Introduction: Obstructive Sleep Apnea and Hypopnea Syndrome (OSAS) is a highly prevalent disease with serious consequences for the patients’ lives. The treatment of the condition is mandatory for the improvement of the quality of life, as well as the life expectancy of the affected individuals. The most frequent treatments provided by dentistry are mandibular advancement devices (MAD) and orthognathic surgery with maxillomandibular advancement (MMA). This is possibly the only treatment option which offers high probability of cure. Objective: The present article provides a narrative review of OSAS from the perspective of 25 years of OSAS treatment clinical experience. Conclusion: MADs are a solid treatment option for primary snoring and mild or moderate OSAS. Patients with severe apnea who are non-adherent to CPAP may also be treated with MADs. Maxillomandibular advancement surgery is a safe and very effective treatment option to OSAS.


2017 ◽  
Vol 96 (3) ◽  
pp. E25-E32 ◽  
Author(s):  
Tang-Chuan Wang ◽  
Yung-An Tsou ◽  
Yi-Fan Wu ◽  
Chia-Chang Huang ◽  
Wesley Wen-Yang Lin ◽  
...  

A titratable thermoplastic mandibular advancement devices (MAD) is clearly an effective treatment option in some patients with obstructive sleep apnea (OSA). Determining which patients may be more likely to respond to treatment with thermoplastic MADs and to adhere to treatment would be of obvious clinical relevance. This was an experimental descriptive study (N = 60). Patients with OSA were instructed to wear a titratable thermoplastic MAD for 3 months. Treatment success was defined as a ≥50% reduction from baseline in the apnea-hypopnea index (AHI) or AHI <10 when wearing MAD. Adherence was defined as MAD use ≥5 nights/week. Treatment was successful in 66.7% of patients and 60.0% were adherent. All Polysomnographic parameters and visual analogue scale scores (sleep quality, snoring, waking refreshed) were significantly improved after treatment. The patients in whom treatment failed had significantly higher neck circumferences (39.3 cm vs. 37.5 cm, p = 0.014), higher baseline AHI values (26.6 vs. 18.0, p = 0.016), and smaller AHI reduction (-31.8 vs -53.1, p < 0.001) than those in the group in whom treatment succeeded. There were no significant differences in Polysomnographic, cephalometric, or visual analogue scale measures between patients for whom treatment was and was not successful, regardless of baseline values or the change rates after the MAD was placed. Titratable thermoplastic MADs can improve indicators of sleep quality, even in patients in whom treatment is considered to have failed.


Sign in / Sign up

Export Citation Format

Share Document